Incidence and Risk of Hypertension and Proteinuria in Cancer Patients Treated with Lenvatinib: A Systematic Review and Meta-analysis.

IF 4.8 2区医学 Q1 ONCOLOGY

Oncologist Pub Date : 2025-07-09 DOI:10.1093/oncolo/oyaf203

Yuma Shibutani, Atsuko Suzuki, Takuro Imaoka, Kazuko Tajiri

{"title":"Incidence and Risk of Hypertension and Proteinuria in Cancer Patients Treated with Lenvatinib: A Systematic Review and Meta-analysis.","authors":"Yuma Shibutani, Atsuko Suzuki, Takuro Imaoka, Kazuko Tajiri","doi":"10.1093/oncolo/oyaf203","DOIUrl":null,"url":null,"abstract":"Background: Published data regarding the overall risks and incidence of hypertension and proteinuria associated with lenvatinib remain unclear.Methods: We performed a systematic review and meta-analysis to quantify the precise risks and incidence of lenvatinib-associated hypertension and proteinuria. We systematically searched PubMed, Cochrane Library, and Web of Science databases for studies on the incidence of hypertension and proteinuria, which were published until April 24, 2023.Results: A total of 10,443 patients were included in the 64 studies identified from the literature. The incidence of all-grade and grade ≥3 hypertension was 50% (95% confidence interval [CI]: 43-58%) and 14% (95% CI: 10-18%) for patients treated with lenvatinib. The incidence of all-grade and grade ≥3 proteinuria was 32% (95% CI: 26-38%) and 6% (95% CI: 4-7%), respectively. Compared with controls, lenvatinib significantly increased the risk of all-grade hypertension (odds ratio [OR]: 2.4, 95% CI: 1.4 - 4.1), grade ≥3 hypertension (OR: 2.7, 95% CI: 1.2 - 6.0), all-grade proteinuria (OR: 3.5, 95% CI: 1.9 - 6.6), and grade ≥3 proteinuria (OR: 2.85, 95% CI: 1.5 - 5.3). Compared to low-dose lenvatinib (≤12 mg/day), high-dose lenvatinib (≥20 mg/day) treatment significantly increased the risks of all-grade hypertension (OR: 4.7, 95% CI: 4.2 - 5.2), grade ≥3 hypertension (OR: 7.7, 95% CI: 6.8 - 8.7), all-grade proteinuria (OR: 1.8, 95% CI: 1.6 - 2.0), and grade ≥3 proteinuria (OR: 1.7, 95% CI: 1.5 - 2.1).Conclusion: Our review revealed that lenvatinib treatment increases the risks of hypertension and proteinuria, particularly with high-dose lenvatinib.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf203","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Published data regarding the overall risks and incidence of hypertension and proteinuria associated with lenvatinib remain unclear.

Methods: We performed a systematic review and meta-analysis to quantify the precise risks and incidence of lenvatinib-associated hypertension and proteinuria. We systematically searched PubMed, Cochrane Library, and Web of Science databases for studies on the incidence of hypertension and proteinuria, which were published until April 24, 2023.

Results: A total of 10,443 patients were included in the 64 studies identified from the literature. The incidence of all-grade and grade ≥3 hypertension was 50% (95% confidence interval [CI]: 43-58%) and 14% (95% CI: 10-18%) for patients treated with lenvatinib. The incidence of all-grade and grade ≥3 proteinuria was 32% (95% CI: 26-38%) and 6% (95% CI: 4-7%), respectively. Compared with controls, lenvatinib significantly increased the risk of all-grade hypertension (odds ratio [OR]: 2.4, 95% CI: 1.4 - 4.1), grade ≥3 hypertension (OR: 2.7, 95% CI: 1.2 - 6.0), all-grade proteinuria (OR: 3.5, 95% CI: 1.9 - 6.6), and grade ≥3 proteinuria (OR: 2.85, 95% CI: 1.5 - 5.3). Compared to low-dose lenvatinib (≤12 mg/day), high-dose lenvatinib (≥20 mg/day) treatment significantly increased the risks of all-grade hypertension (OR: 4.7, 95% CI: 4.2 - 5.2), grade ≥3 hypertension (OR: 7.7, 95% CI: 6.8 - 8.7), all-grade proteinuria (OR: 1.8, 95% CI: 1.6 - 2.0), and grade ≥3 proteinuria (OR: 1.7, 95% CI: 1.5 - 2.1).

Conclusion: Our review revealed that lenvatinib treatment increases the risks of hypertension and proteinuria, particularly with high-dose lenvatinib.

查看原文本刊更多论文

Lenvatinib治疗的癌症患者高血压和蛋白尿的发病率和风险：一项系统回顾和荟萃分析。

背景：关于lenvatinib相关的高血压和蛋白尿的总体风险和发生率的已发表数据仍不清楚。方法：我们进行了一项系统回顾和荟萃分析，以量化lenvatinib相关高血压和蛋白尿的确切风险和发生率。我们系统地检索了PubMed、Cochrane图书馆和Web of Science数据库中关于高血压和蛋白尿发病率的研究，这些研究发表到2023年4月24日。结果：从文献中确定的64项研究共纳入10443例患者。lenvatinib组患者的全级和≥3级高血压发生率分别为50%（95%可信区间[CI]: 43-58%）和14% （95% CI: 10-18%）。全级和≥3级蛋白尿的发生率分别为32% （95% CI: 26-38%）和6% （95% CI: 4-7%）。与对照组相比，lenvatinib显著增加了所有级别高血压（比值比[OR]: 2.4, 95% CI: 1.4 - 4.1）、≥3级高血压（OR: 2.7, 95% CI: 1.2 - 6.0）、所有级别蛋白尿（OR: 3.5, 95% CI: 1.9 - 6.6）和≥3级蛋白尿（OR: 2.85, 95% CI: 1.5 - 5.3）的风险。与低剂量lenvatinib（≤12mg /天）相比，高剂量lenvatinib（≥20mg /天）治疗显著增加了全级别高血压（OR: 4.7, 95% CI: 4.2 - 5.2）、≥3级高血压（OR: 7.7, 95% CI: 6.8 - 8.7）、全级别蛋白尿（OR: 1.8, 95% CI: 1.6 - 2.0）和≥3级蛋白尿（OR: 1.7, 95% CI: 1.5 - 2.1）的风险。结论：我们的综述显示lenvatinib治疗增加高血压和蛋白尿的风险，特别是大剂量lenvatinib。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncologist 医学-肿瘤学

CiteScore

10.40

自引率

3.40%

发文量

309

审稿时长

3-8 weeks

期刊介绍： The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.